UBS Group
ONC

UBS Group’s BeOne Medicines Ltd ONC Stock Holding History

UBS Group’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-93,720
Closed -$16.7M – 10075
2023
Q2 		$16.7M Buy
+93,720
New +$21.6M 0.01% 1578
2018
Q3 		– Sell
-12,500
Closed -$1.92M – 8329
2018
Q2 		$1.92M Buy
+12,500
New +$2.23M ﹤0.01% 3216

Other funds holding ONC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

UBS Group's ONC Position: Q1 2026 in Review

UBS Group increased its BeOne Medicines Ltd (ONC) stake by 173% in Q1 2026, buying an estimated $85.2M and bringing the position to 415,330 shares worth $123M. The position accounts for 0.02% of the portfolio, ranked #895.

UBS Group first reported a position in ONC in Q1 2016 and has held it in 39 quarters since. 282 funds tracked by Wall St. Rank hold ONC as of Q1 2026.

  • UBS Group held 415,330 shares of BeOne Medicines Ltd worth $123M as of Q1 2026.
  • UBS Group bought 263,243 BeOne Medicines Ltd shares in Q1 2026, an estimated $85.2M.
  • BeOne Medicines Ltd made up 0.02% of UBS Group's portfolio in Q1 2026, its #895 holding.
  • UBS Group first reported a position in BeOne Medicines Ltd in Q1 2016 and has held it in 39 quarters since.
  • 282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.